Health
FDA Approves Landmark Pancreatic Cancer Drug Rasonque
FDA approves Rasonque (daraxonrasib), a first-in-class targeted therapy that nearly doubled survival in metastatic pancreatic cancer patients.
—6 min read
Tag
#Daraxonrasib
3 articles
HealthMedical Research
Experimental Pill Doubles Survival in Pancreatic Cancer
New oral drug daraxonrasib nearly doubled survival in metastatic pancreatic cancer patients, marking a breakthrough against one of the deadliest cancers.
—5 min read
HealthMedical Breakthrough
Experimental Pill Nearly Doubles Pancreatic Cancer Survival
A new experimental pill nearly doubles survival for advanced pancreatic cancer patients, targeting the long-undruggable KRAS mutation.
—5 min read